SWM
CPRX

Spire Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Spire Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,100
Closed -$306K – 2383
2025
Q2 		$306K Sell
14,100
-4,329
-23% -$102K 0.01% 635
2025
Q1 		$447K Buy
18,429
+4,000
+28% +$90.1K 0.01% 599
2024
Q4 		$301K Buy
14,429
+13,429
+1,343% +$288K 0.01% 705
2024
Q3 		$19.9K Sell
1,000
-38
-4% -$704 ﹤0.01% 1441
2024
Q2 		$16.1K Hold
1,038
– – ﹤0.01% 1514
2024
Q1 		$16.5K Hold
1,038
– – ﹤0.01% 1570
2023
Q4 		$15.1K Hold
1,038
– – ﹤0.01% 1626
2023
Q3 		$12.1K Hold
1,038
– – ﹤0.01% 1668
2023
Q2 		$14K Buy
+1,038
New +$14.9K ﹤0.01% 1711

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Spire Wealth Management's CPRX Position: Q3 2025 in Review

Spire Wealth Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2025, closing a stake of 14,100 shares — an estimated $306K sold.

Spire Wealth Management first reported a position in CPRX in Q2 2023 and held it in 9 quarters. The position peaked at $447K in Q1 2025. 360 funds tracked by Wall St. Rank hold CPRX as of Q3 2025.

  • Spire Wealth Management reported no remaining Catalyst Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Spire Wealth Management sold 14,100 Catalyst Pharmaceutical shares in Q3 2025, an estimated $306K.
  • Spire Wealth Management first reported a position in Catalyst Pharmaceutical in Q2 2023 and held it in 9 quarters.
  • Spire Wealth Management's Catalyst Pharmaceutical position peaked at $447K in Q1 2025.
  • 360 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2025.

Based on Spire Wealth Management's 13F filing for Q3 2025, filed 23 Oct 2025.